Patents by Inventor Renier Brentjens

Renier Brentjens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210393689
    Abstract: Provided are chimeric antigen receptors (CARs), which contain antibody portions specific to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and polynucleotides that encode CARs specific for GPRC5D. The disclosure further relates to genetically engineered cells, containing such GPRCSD-binding receptors, and uses thereof in adoptive cell therapy.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 23, 2021
    Applicants: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Blythe D. SATHER, Eric L. SMITH, Cyr DE IMUS, Kimberly HARRINGTON, Jon JONES, Aye CHEN, Semih TAREEN, Erik HESS, Stefan PONKO, Audrey OLSHEFSKY, Carlos FERNANDEZ DE LARREA, Renier BRENTJENS
  • Patent number: 7446190
    Abstract: Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 ?-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target. When expressed, for example in T-lymphocytes from the individual to be treated for a condition associated with the selected target, a T cell immune response is stimulated in the individual to the target cells. The chimeric TCR's are able to provide both the activation and the co-stimulation signals from a single molecule to more effectively direct T-lymphocyte cytotoxicity against the selected target and T-lymphocyte proliferation.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: November 4, 2008
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Michel Sadelain, Renier Brentjens, John Maher
  • Publication number: 20040043401
    Abstract: Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 &zgr;-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target. When expressed, for example in T-lymphocytes from the individual to be treated for a condition associated with the selected target, a T cell immune response is stimulated in the individual to the target cells. The chimeric TCR's are able to provide both the activation and the co-stimulation signals from a single molecule to more effectively direct T-lymphocyte cytotoxicity against the selected target and T-lymphocyte proliferation.
    Type: Application
    Filed: May 28, 2003
    Publication date: March 4, 2004
    Applicant: Sloan Kettering Institute for Cancer Research
    Inventors: Michel Sadelain, Renier Brentjens, John Maher